targeting calpain-2 for people living with amyotrophic lateral sclerosis (ALS). With the clinical hold lifted, Amylyx is now working to open U.S. sites for screening, enrollment, and dosing.

Delve into the increasingly dynamic landscape of ALS treatment development with thirteen companies advancing candidates in ...

Amylyx Pharmaceuticals, Inc. ("Amylyx" or the "Company") today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold placed on the Phase 1 clinical trial of AMX0114, ...

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that remains incurable, despite decades of basic and clinical research. Key stakeholders—including the US National ...

After raising questions surrounding dosing levels, the FDA has freed Amylyx’s early-stage amyotrophic lateral sclerosis (ALS) ...

At the beginning of 2025 I knocked on the door of Cai Lei former executive of a major listed company in Beijing When I entered the room he was par ...

The US Food and Drug Administration (FDA) has granted approval for Zydus Lifesciences to proceed with a randomised Phase IIb ...

As state legislatures are beginning their 2025 sessions, the ALS Association has released its latest ALS State Policy Report ...

The S&P BSE Sensex ended the day 566 points or 0.75% up at 76,404, while the NSE Nifty 50 gained 130.7 points or 0.57% higher ...

“Based on several preclinical efficacy studies and what is known about the central role of calpain-2 in the process of axonal degeneration, we believe AMX0114 has the potential to be a treatment ...

Introduction Who doesn’t want to live an easy life? The sole reason for Human civilization’s advancement in the technological ...